Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

Guillain-Barré Syndrome

Guillain-Barré Syndrome (GBS) is an inflammatory autoimmune disease that affects the peripheral nervous system.

What are the other Names for this Condition? (Also known as/Synonyms)

  • GBS (Guillain-Barré Syndrome)
  • Landry's Ascending Paralysis
  • Post-Infectious Polyneuritis

What is Guillain-Barré Syndrome? (Definition/Background Information)

  • Guillain-Barré Syndrome (GBS) is an inflammatory autoimmune disease that affects the peripheral nervous system
  • The disorder is characterized by ascending weakness and paralysis, often beginning in the feet and legs and progressing to the trunk, arms, and face
  • In severe cases, paralysis of the muscles involved in breathing can lead to respiratory failure
  • In over two-thirds of the cases, a respiratory or GI infection precedes the development of this autoimmune disorder, which can be confirmed through study of the signs and symptoms and a cerebral fluid analysis
  • The first line of treatment of Guillain-Barré Syndrome is the administration of IVIG (intravenous immunoglobulin), with plasma transfusion, as required
  • The prognosis is generally good with appropriate therapy, though in a small number of cases, a relapse may occur

Who gets Guillain-Barré Syndrome? (Age and Sex Distribution)

  • Children and adults of all ages may be affected by Guillain-Barré Syndrome; though the highest incident rate is seen in individuals 50-74 years of age
  • There is a slightly higher incidence in males than females
  • GBS is found worldwide during all seasons, affecting all racial and ethnic groups

What are the Risk Factors for Guillain-Barré Syndrome? (Predisposing Factors)

The risk factors of Guillain-Barré Syndrome may include the following:

  • Guillain-Barré Syndrome frequently occurs 1-3 weeks after a respiratory or gastrointestinal infection (in approximately 70% of cases)
  • The known triggers include infection with the following bacteria and viruses:
  • Campylobacter jejuni (bacteria causing gastrointestinal infection)
  • Cytomegalovirus
  • Epstein-Barr virus (viruses causing infectious mononucleosis)
  • Mycoplasma pneumoniae (bacteria causing atypical pneumonia)
  • Rarely, vaccinations for rabies and influenza have triggered GBS

It is important to note that having a risk factor does not mean that one will get the condition. A risk factor increases ones chances of getting a condition compared to an individual without the risk factors. Some risk factors are more important than others.

Also, not having a risk factor does not mean that an individual will not get the condition. It is always important to discuss the effect of risk factors with your healthcare provider.

What are the Causes of Guillain-Barré Syndrome? (Etiology)

  • Guillain-Barré Syndrome is caused by destruction of myelin, the coating around peripheral nerve fibers, by the immune system
  • Inappropriate activation of the immune system during the preceding infection or vaccination is thought to result in the production of antibodies that attack myelin
  • Loss of myelin causes dysfunction of nervous system signaling, which leads to weakness and paralysis

What are the Signs and Symptoms of Guillain-Barré Syndrome?

The signs and symptoms of Guillain-Barré Syndrome are the following:

  • Initially, the symptoms include numbness and weakness of the fingers and toes, and urinary retention
  • This is soon followed by increasing symmetrical weakness over a period of 1-2 weeks, usually starting in the lower extremities and moving up to include the arms and face
  • The symptoms are usually at their worst after 4 weeks and many patients are unable to walk, by this time
  • Aches and pains of muscles in back, hips, and legs are common
  • Due to paralysis of muscles involved in respiration, one-third of patients may require endotracheal intubation (breathing tube) and mechanical ventilation, until they recover

How is Guillain-Barré Syndrome Diagnosed?

A diagnosis of Guillain-Barré Syndrome may involve:

  • Physical examination with detailed medical history evaluation: The diagnosis of GBS is made based on the characteristic symptoms of rapidly-acquired paralysis and CSF analysis
  • Analysis of cerebral spinal fluid (CSF): CSF analysis typically shows increased levels of protein and a normal cell count, approximately 1-week after the onset of symptoms
  • Electromyography studies to assess for decreased nerve conduction may be done to confirm the diagnosis

Many clinical conditions may have similar signs and symptoms. Your healthcare provider may perform additional tests to rule out other clinical conditions to arrive at a definitive diagnosis.

What are the possible Complications of Guillain-Barré Syndrome?

The following complications may occur as a result of Guillain-Barré Syndrome:

  • In serious cases of GBS, complications can arise from prolonged immobilization and/or respiratory failure
  • Patients that have difficulty swallowing have an increased risk for aspiration pneumonia. In such cases, endotracheal intubation may be necessary
  • Patients are at risk for developing cardiac arrhythmias
  • Blood pressure changes and dizziness are also common
  • 3-5% of patients may have a relapse of symptoms, often following a long asymptomatic period of many years

How is Guillain-Barré Syndrome Treated?

The treatment for Guillain-Barré Syndrome could include the following measures:

  • Intravenous immune globulin (IVIG), a blood product, is the primary treatment. Plasma exchange may also be used
  • Heparin may be given to help prevent venous thromboembolism (blood clots) from forming as a consequence of immobilization
  • Most patients are admitted to the hospital for close observation

How can Guillain-Barré Syndrome be Prevented?

Currently, there are no known methods to prevent Guillain-Barré Syndrome occurrence.

What is the Prognosis of Guillain-Barré Syndrome? (Outcomes/Resolutions)

  • More than 95% of patients recover from Guillain-Barré Syndrome, although recovery may take several weeks to months
  • Recovery is fairly spontaneous and typically occurs 2-4 weeks after patient reaches their maximal weakness
  • 10% of patients have permanent residual weakness or numbness, usually of the feet and toes 

Additional and Relevant Useful Information for Guillain-Barré Syndrome:

The following DoveMed website link is a useful resource for additional information:


What are some Useful Resources for Additional Information?

Guillain-Barré Syndrome Foundation    
GBS/CIDP Foundation International
The Holly Building - 104 1/2 Forrest Avenue - Narberth, PA 19072    
Phone: (610) 667-0131
Toll-Free: (866) 224-3301    
Fax: (610) 667-7036        
Website: http://www.guillain-barre.com

National Institute of Neurological Disorders and Stroke
P.O. Box 5801 Bethesda, MD 20824
Phone: (301) 496-5751
Toll-Free: (800) 352-9424
TDD: (301) 468-5981
Fax: (301) 402-2186
Email: me20t@nih.gov
Website: http://www.ninds.nih.gov

References and Information Sources used for the Article:

Guillain-Barré syndrome and related disorders. In MD Consult [online database].  Updated March 17, 2001.  (Accessed November 28, 2015)

Hauser Stephen L, Asbury Arthur K, "Chapter 380. Guillain-Barré Syndrome and Other Immune-Mediated Neuropathies" (Chapter). Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine, 17e: http://www.accessmedicine.com.proxy.cc.uic.edu/content.aspx?aID=2907353.

Ropper AH, Samuels MA, "Chapter 46. Diseases of the Peripheral Nerves" (Chapter). Ropper AH, Samuels MA: Adams and Victor's Principles of Neurology, 9e: http://www.accessmedicine.com.proxy.cc.uic.edu/content.aspx?aID=3641268.

Stone C. K, Cooney Derek R, "Chapter 35. Neurologic Emergencies" (Chapter). Stone CK, Humphries RL: CURRENT Diagnosis & Treatment: Emergency Medicine, 6e: http://www.accessmedicine.com.proxy.cc.uic.edu/content.aspx?aID=3107773.

Helpful Peer-Reviewed Medical Articles:

Arcila-Londono, X., & Lewis, R. A. (2012). Guillain-Barre syndrome. Semin Neurol, 32(3), 179-186. doi: 10.1055/s-0032-1329196

Rajabally, Y. A., & Uncini, A. (2012). Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry, 83(7), 711-718. doi: 10.1136/jnnp-2011-301882

Rigamonti, A., Basso, F., Scaccabarozzi, C., & Lauria, G. (2012). Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-Barre syndrome: case report and review of the literature. J Peripher Nerv Syst, 17(3), 356-360. doi: 10.1111/j.1529-8027.2012.00416.x

Walling, A. D., & Dickson, G. (2013). Guillain-Barre syndrome. Am Fam Physician, 87(3), 191-197.

Yuki, N., & Hartung, H. P. (2012). Guillain–Barré syndrome. New England Journal of Medicine, 366(24), 2294-2304.

Hahn, A. F. (1998). Guillain-barré syndrome. The lancet, 352(9128), 635-641.

Kuwabara, S. (2004). Guillain-barré syndrome. Drugs, 64(6), 597-610.

Hughes, R. A., & Cornblath, D. R. (2005). Guillain-barre syndrome. The Lancet, 366(9497), 1653-1666.

Winer, J. B. (2001). Guillain Barre syndrome. Molecular Pathology, 54(6), 381.

Newswanger, D. L., & Warren, C. R. (2004). Guillain-Barré syndrome. American family physician, 69(10).

Seneviratne, U. (2000). Guillain-Barré syndrome. Postgraduate medical journal, 76(902), 774-782.

Burns, T. M. (2008, April). Guillain-Barré syndrome. In Seminars in neurology (Vol. 28, No. 2, pp. 152-167). [New York]: Thieme-Stratton Inc.,[c1981-.